Condition: Type 1 Diabetes (T1D) · Metabolic Diseases · Glucose Metabolism Disorders · Sponsor: University of Washington
The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center/Diabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.
This description comes directly from the study's public registry record.
Amanda Bard, MMS, MS, CCRC · 206-685-2069 · abard@uw.edu
Always discuss trial participation with your own doctor first.
| University of Washington Medicine Diabetes Institute (UWMDI) | Seattle, Washington, United States | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07699380